Kolmar BioTech. Inc.

As of June 30, 2026, Kolmar BioTech. Inc. carries a market capitalization of 39.18B, placing it among publicly traded companies globally. Its enterprise value stands at 56.86B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Kolmar BioTech. Inc. has 16.67M shares outstanding.

As of June 30, 2026, Kolmar BioTech. Inc. trades at a trailing price-to-earnings ratio of 31.72. The price-to-sales ratio is 0.89, and the price-to-book ratio stands at 1.47.

As of June 30, 2026, Kolmar BioTech. Inc. trades at an EV/EBITDA multiple of 25.75 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.29 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 56.86B versus a market cap of 39.18B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Kolmar BioTech. Inc. maintains a current ratio of 0.55, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 125.44, indicating elevated leverage, while an interest coverage ratio of 0.68 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Kolmar BioTech. Inc. posted a return on equity (ROE) of 4.77, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) is negative at -0.71, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 1.27, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 6.53, useful for judging operating efficiency across full business cycles. The company generates approximately 332.34M in revenue per employee across its workforce of 133.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.65 indicates how many times Kolmar BioTech. Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 23, 2026, Kolmar BioTech. Inc.'s stock has gained approximately 18.08% over the past 52 weeks. The 50-day moving average sits at 2,205.10, while the 200-day moving average is 2,462.61.

Over the twelve months ended June 30, 2026, Kolmar BioTech. Inc. generated 44.20B in revenue and converted that into 1.24B in net income, yielding earnings per share of 8.05. EBITDA reached 2.21B, while operating income came in at -228.64M.

As of June 30, 2026, Kolmar BioTech. Inc. holds 15.65B in cash and equivalents against 33.34B in total debt, resulting in a net debt position of 17.33B. Total book value stands at 26.58B, with working capital of -29.22B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Kolmar BioTech. Inc. posted a gross margin of 30.20, reflecting its pricing power and cost economics. The operating margin of -0.52 and net profit margin of 2.80 provide insight into operational efficiency.

Kolmar BioTech. Inc.'s most recent stock split took place on August 6, 2019 with a 5:2 split ratio.

As of June 30, 2026, Kolmar BioTech. Inc. has an Altman Z-Score of 0.01, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.